Business
Lifeline Biotechnologies' (LLBO) Affiliate, Cyrcadia, Registers Clinical Trial
Lifeline Biotechnologies' (LLBO) Affiliate, Cyrcadia, Registers Clinical Trial.
About this update from Lifeline Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n Lifeline Biotechnologies' (LLBO) Affiliate, Cyrcadia, Registers Clinical Trial\n \n \nLifeline Biotechnologies' (LLBO) Affiliate, Cyrcadia, Registers Clinical Trial\n \n RENO, NV--(Marketwired - Aug 11, 2015) - Lifeline Biotechnologies (OTC PINK: LLBO) announces its affiliate, Cyrcadia, has listed its clinical trial on ClinicalTrials.gov for its wearable breast cancer early detection device at El Camino Hospital, Mountain View, California and upcoming additional clinical study sites. ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database currently holding registrations from over 130,000 trials and more than 170 countries around the world.\n For those interested in learning more about the Cyrcadia clinical studies, ClinicalTrials.gov is the registry to use, including all details about the study and its status. It is the only location where Cyrcadia will provide information about the studies and will update the registry from time to time. All information desired about the clinical studies can be obtained there and will not otherwise be provided by Cyrcadia, its staff or other related parties. All details about the study, including descriptions, eligibility and contacts, can be obtained there. Please follow this link: ClinicalTrials.gov/Cyrcadia or go to the ClinicalTrials.gov website using the identifier NCT02511301 to learn more and follow progress of the study as it is reported.\n Utilizing Lifeline's previous FDA cleared device as a predicate, Cyrcadia Health™ (a division of Cyrcadia, Inc.) is combining the Company's fourth generation, wearable device technology, made by Flextronics, and the SalesForce database software, to track the clinical results. Previous trials, conducted by Lifeline Biotechnologies, tested over 500 participants in developing, validating and patenting the technology. Utilizing the non-compressive, non-irradiative technology demonstrated significant promise in addressing the dense breast tissue population by using machine-learning predictive algorithms. With a higher propensity for cancer and limitations of current imaging standards, such as mammography, Cyrcadia Health's screening technology could provide a much earlier alert to the state of cance...